Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited announced that safety data from the Phase 1a/1b clinical trial of their drug candidate PYC-003, aimed at treating Polycystic Kidney Disease, will be presented at the ANZSN conference. The data from the trial’s completed dose cohorts show a favorable safety profile, with no serious adverse events or signs of renal injury, supporting the drug’s potential efficacy and safety in further trials.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases that currently have no available options. The company is engaged in three clinical-stage drug development programs, including PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD).
Average Trading Volume: 635,828
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$758.2M
See more data about PYC stock on TipRanks’ Stock Analysis page.